AG˹ٷ

STOCK TITAN

[144] BridgeBio Pharma, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 144 summary for BridgeBio Pharma, Inc. (BBIO)

This Form 144 reports an insider sale on 08/05/2025: 17,167 common shares sold through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) with an aggregate market value of $841,183.00. The filing lists 189,880,720 shares outstanding. The securities were acquired and paid for on 08/05/2025 via a stock option exercise from the issuer with cash payment. The filer reports "Nothing to Report" for securities sold in the past three months.

Note: Several filer and issuer contact fields in the form are blank in the provided text.

Riepilogo del Modulo 144 per BridgeBio Pharma, Inc. (BBIO)

Questo Modulo 144 segnala una vendita da insider il 08/05/2025: 17,167 azioni ordinarie vendute tramite Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) con un valore di mercato complessivo di $841,183.00. Il deposito indica 189,880,720 azioni in circolazione. I titoli sono stati acquisiti e pagati il 08/05/2025 tramite un esercizio di opzioni su azioni dall'emittente con pagamento in contanti. Il dichiarante riporta "Nothing to Report" per titoli venduti negli ultimi tre mesi.

Nota: Diversi campi di contatto del dichiarante e dell'emittente nel modulo risultano vuoti nel testo fornito.

Resumen del Formulario 144 de BridgeBio Pharma, Inc. (BBIO)

Este Formulario 144 informa una venta de un insider el 08/05/2025: 17,167 acciones comunes vendidas a través de Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) con un valor de mercado agregado de $841,183.00. La presentación indica 189,880,720 acciones en circulación. Los valores fueron adquiridos y pagados el 08/05/2025 mediante un ejercicio de opciones sobre acciones del emisor con pago en efectivo. El declarante informa "Nothing to Report" respecto a valores vendidos en los últimos tres meses.

Nota: Varios campos de contacto del declarante y del emisor en el formulario aparecen en blanco en el texto proporcionado.

BridgeBio Pharma, Inc. (BBIO) Form 144 요약

� Form 144� 08/05/2025� 내부� 매각� 보고합니�: 17,167 보통주가 Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004)� 통해 매각되었으며, � 시가총액 $841,183.00입니�. 제출서에� 189,880,720 주의 발행주식수가 기재되어 있습니다. 해당 증권은 발행인으로부터의 스톡 옵션 행사� 통해 08/05/2025� 현금으로 취득·지급되었습니다. 제출인은 지� � 달간 매도� 증권� 대� "Nothing to Report"라고 보고합니�.

참고: 제공� 텍스트의 양식에서 제출� � 발행� 연락� 일부 필드가 비어 있습니다.

Résumé du formulaire 144 pour BridgeBio Pharma, Inc. (BBIO)

Ce formulaire 144 signale une cession d'initié le 08/05/2025 : 17,167 actions ordinaires vendues via Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) pour une valeur marchande totale de $841,183.00. Le dépôt indique 189,880,720 actions en circulation. Les titres ont été acquis et payés le 08/05/2025 par exercice d'options sur actions émises par l'émetteur avec paiement en è. Le déclarant indique "Nothing to Report" concernant les titres vendus au cours des trois derniers mois.

Remarque : Plusieurs champs de contact du déclarant et de l'émetteur dans le formulaire sont laissés vides dans le texte fourni.

Form 144 Zusammenfassung für BridgeBio Pharma, Inc. (BBIO)

Dieses Formular 144 meldet einen Insider-Verkauf am 08/05/2025: 17,167 Stammaktien wurden über Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) verkauft mit einem Gesamtmarktwert von $841,183.00. Die Einreichung gibt 189,880,720 ausstehende Aktien an. Die Wertpapiere wurden am 08/05/2025 durch Ausübung von Aktienoptionen vom Emittenten erworben und bar bezahlt. Der Einreicher gibt für in den letzten drei Monaten verkaufte Wertpapiere "Nothing to Report" an.

Hinweis: Mehrere Kontaktfelder des Einreichers und des Emittenten im Formular sind im vorliegenden Text leer.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider sale via option exercise on 08/05/2025; transaction size is immaterial versus total outstanding shares.

The filing documents a single transaction: 17,167 common shares sold through Morgan Stanley Smith Barney for an aggregate $841,183.00. Acquisition and payment occurred the same day by stock option exercise and cash. No other insider sales were reported in the prior three months. Impact to capitalization or control is minimal given the reported outstanding share count of 189,880,720. Investors should note the transaction type (option exercise) when interpreting insider intent, but the filing contains no additional material disclosures.

TL;DR: Disclosure complies with Rule 144 mechanics; no red flags in the notice itself.

The Form 144 provides required broker, share count, aggregate value, and acquisition details, and includes the issuer-outstanding share figure. The filer affirms no undisclosed material adverse information. Several administrative fields (filer CIK, issuer name/address) appear blank in the extracted text; ensure complete records are filed with the SEC. Overall governance implications are neutral based on this single, routine option-exercise sale.

Riepilogo del Modulo 144 per BridgeBio Pharma, Inc. (BBIO)

Questo Modulo 144 segnala una vendita da insider il 08/05/2025: 17,167 azioni ordinarie vendute tramite Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) con un valore di mercato complessivo di $841,183.00. Il deposito indica 189,880,720 azioni in circolazione. I titoli sono stati acquisiti e pagati il 08/05/2025 tramite un esercizio di opzioni su azioni dall'emittente con pagamento in contanti. Il dichiarante riporta "Nothing to Report" per titoli venduti negli ultimi tre mesi.

Nota: Diversi campi di contatto del dichiarante e dell'emittente nel modulo risultano vuoti nel testo fornito.

Resumen del Formulario 144 de BridgeBio Pharma, Inc. (BBIO)

Este Formulario 144 informa una venta de un insider el 08/05/2025: 17,167 acciones comunes vendidas a través de Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) con un valor de mercado agregado de $841,183.00. La presentación indica 189,880,720 acciones en circulación. Los valores fueron adquiridos y pagados el 08/05/2025 mediante un ejercicio de opciones sobre acciones del emisor con pago en efectivo. El declarante informa "Nothing to Report" respecto a valores vendidos en los últimos tres meses.

Nota: Varios campos de contacto del declarante y del emisor en el formulario aparecen en blanco en el texto proporcionado.

BridgeBio Pharma, Inc. (BBIO) Form 144 요약

� Form 144� 08/05/2025� 내부� 매각� 보고합니�: 17,167 보통주가 Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004)� 통해 매각되었으며, � 시가총액 $841,183.00입니�. 제출서에� 189,880,720 주의 발행주식수가 기재되어 있습니다. 해당 증권은 발행인으로부터의 스톡 옵션 행사� 통해 08/05/2025� 현금으로 취득·지급되었습니다. 제출인은 지� � 달간 매도� 증권� 대� "Nothing to Report"라고 보고합니�.

참고: 제공� 텍스트의 양식에서 제출� � 발행� 연락� 일부 필드가 비어 있습니다.

Résumé du formulaire 144 pour BridgeBio Pharma, Inc. (BBIO)

Ce formulaire 144 signale une cession d'initié le 08/05/2025 : 17,167 actions ordinaires vendues via Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) pour une valeur marchande totale de $841,183.00. Le dépôt indique 189,880,720 actions en circulation. Les titres ont été acquis et payés le 08/05/2025 par exercice d'options sur actions émises par l'émetteur avec paiement en è. Le déclarant indique "Nothing to Report" concernant les titres vendus au cours des trois derniers mois.

Remarque : Plusieurs champs de contact du déclarant et de l'émetteur dans le formulaire sont laissés vides dans le texte fourni.

Form 144 Zusammenfassung für BridgeBio Pharma, Inc. (BBIO)

Dieses Formular 144 meldet einen Insider-Verkauf am 08/05/2025: 17,167 Stammaktien wurden über Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) verkauft mit einem Gesamtmarktwert von $841,183.00. Die Einreichung gibt 189,880,720 ausstehende Aktien an. Die Wertpapiere wurden am 08/05/2025 durch Ausübung von Aktienoptionen vom Emittenten erworben und bar bezahlt. Der Einreicher gibt für in den letzten drei Monaten verkaufte Wertpapiere "Nothing to Report" an.

Hinweis: Mehrere Kontaktfelder des Einreichers und des Emittenten im Formular sind im vorliegenden Text leer.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did BridgeBio (BBIO) report on Form 144 dated 08/05/2025?

The Form 144 reports sale of 17,167 common shares on 08/05/2025 via Morgan Stanley Smith Barney LLC with aggregate value $841,183.00.

How were the BBIO shares acquired and paid for according to the filing?

The securities were acquired by stock option exercise from the issuer on 08/05/2025 and payment was made in cash on the same date.

How many BBIO shares were outstanding as reported in the Form 144?

The filing lists 189,880,720 shares outstanding.

Were there any other insider sales by the filer in the prior three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

Which broker handled the transaction in the BBIO Form 144?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

8.90B
164.71M
4.96%
97.09%
10.26%
Biotechnology
Pharmaceutical Preparations
United States
PALO ALTO